Avalo Therapeutics, Inc., a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with the appointment of Taylor Boyd to Chief Business Officer.
